(secondQuint)Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy.

 This is a single-arm, open-label, multicenter, phase II clinical trial design with an early stopping rules.

 PHA-848125AC will be administered to patients with recurrent metastatic unresectable B3 thymoma or thymic carcinoma who have received more than one line of prior systemic therapy for advanced / metastatic disease.

 The intent of the study is to assess the antitumor activity of PHA-848125AC and ultimately to improve the outcome of the patients.

 The primary end point for this study is a progression free survival rate of 3 months.

.

 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy@highlight

The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.

